Abstract | BACKGROUND: METHODS: The differential expression of G9a in cancer and normal tissues was assessed using an array of 28 paired samples. Tissue specimens from 94 patients with endometrial cancer who underwent primary surgery were immunohistochemically evaluated for G9a and E-cadherin expression. To assess the biologic role of G9a in endometrial cancer, G9a was either stably knocked down or knocked down using a tetracycline-controllable system in endometrial cancer cells, followed by functional assays. RESULTS: Increased G9a expression was identified in endometrial cancer tissues, and its expression was specifically correlated with deep myometrial invasion. Cell invasiveness was inhibited by an RNAi-mediated knockdown of G9a in invasive endometrial cancer cells in vitro and in vivo. An important mediator of G9a-induced tumor invasion is the epigenetic silencing of E-cadherin. Knockdown of G9a restored E-cadherin expression by reducing H3K9me2 levels and decreasing CDH1 promoter DNA methyltransferase recruitment. Knockdown of RNAi-mediated E-cadherin substantially relieved the invasion suppression imposed by G9a suppression. A significant negative correlation between G9a and E-cadherin expression was observed in endometrial cancer (Spearman's rho, -0.27; P = 0.02). CONCLUSIONS: This study provides the first clear evidence that G9a contributes to endometrial cancer progression. Mechanistic investigations suggest that E-cadherin repression mediates the effects of G9a. Targeting G9a-mediated epigenetic pathway dysregulation may be a therapeutic strategy for endometrial cancers.
|
Authors | Sheng-Mou Hsiao, Min-Wei Chen, Chi-An Chen, Ming-Hsien Chien, Kuo-Tai Hua, Michael Hsiao, Min-Liang Kuo, Lin-Hung Wei |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 22 Suppl 3
Pg. S1556-65
(Dec 2015)
ISSN: 1534-4681 [Electronic] United States |
PMID | 25613390
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Cadherins
- Histocompatibility Antigens
- EHMT2 protein, human
- Histone-Lysine N-Methyltransferase
|
Topics |
- Animals
- Apoptosis
- Biomarkers, Tumor
(genetics, metabolism)
- Blotting, Western
- Cadherins
(antagonists & inhibitors, genetics, metabolism)
- Cell Movement
- Cell Proliferation
- Chromatin Immunoprecipitation
- Endometrial Neoplasms
(genetics, metabolism, pathology)
- Epigenesis, Genetic
- Female
- Gene Expression Regulation, Neoplastic
- Histocompatibility Antigens
(genetics, metabolism)
- Histone-Lysine N-Methyltransferase
(genetics, metabolism)
- Humans
- Immunoenzyme Techniques
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Middle Aged
- Myometrium
(metabolism, pathology)
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Staging
- Prognosis
- Promoter Regions, Genetic
- Real-Time Polymerase Chain Reaction
- Retrospective Studies
- Survival Rate
- Tumor Cells, Cultured
|